Reunion Neuroscience has achieved positive topline results from the Phase 2 trial of RE104, a synthetic
#psychedelic, in postpartum depression. This marks an exciting milestone for their mission. Remarkably, 71% of patients experienced remission of symptoms within 7 days.
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)...
